OcuTerra Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- OcuTerra Therapeutics's estimated annual revenue is currently $930k per year.
- OcuTerra Therapeutics's estimated revenue per employee is $77,500
- OcuTerra Therapeutics's total funding is $35M.
Employee Data
- OcuTerra Therapeutics has 12 Employees.
- OcuTerra Therapeutics grew their employee count by 20% last year.
OcuTerra Therapeutics's People
| Name | Title | Email/Phone |
|---|
OcuTerra Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is OcuTerra Therapeutics?
Non-Invasive, Transformational Approach to Treating Retinal Disease. OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity
keywords:N/A
$35M
Total Funding
12
Number of Employees
$930k
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
OcuTerra Therapeutics News
2022-04-06 - OcuTerra Appoints Majid Anderesi, MD, as Vice President of ...
BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (OcuTerra), a clinical stage ophthalmology company developing innovative drugs to...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 12 | 0% | $101.2M |
#2 | $1M | 12 | N/A | N/A |
#3 | $1M | 12 | N/A | N/A |
#4 | $1M | 12 | N/A | N/A |
#5 | $1M | 12 | N/A | N/A |